ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease Activity"

  • Abstract Number: 1724 • ACR Convergence 2020

    A Feasible and Efficient Approach to Implementing Rheumatoid Arthritis Disease Activity Measure in a Busy Rheumatology Clinic: A Quality Improvement Project

    Ali H.Ali1, Amani Elghafri2, Mosaab Mohameden3, Mandeep Sidhu2 and Candice Reyes Yuvienco4, 1University of California San Francisco Fresno, Fresno, CA, 2University of California San Francisco Fresno, Fresno, 3University of Cincinnati, Cincinnati, OH, 4University of California San Francisco Fresno, Clovis, CA

    Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has witnessed a substantial change over last the 20 years, with disease remission becoming an achievable goal. Treat-to-target…
  • Abstract Number: 1818 • ACR Convergence 2020

    IgG and IgA Autoantibodies Against L1 ORF1p Expressed in Granulocytes Correlate with Granulocyte Consumption and Disease Activity in Pediatric Systemic Lupus Erythematosus

    Kennedy Ukadike1, Kathryn Ni1, Victoria Carter1, Martin Taylor2, John LaCava3, Lauren Pachman4, Xiaoxing Wang1, Mary Eckert5, Anne Stevens1, Christian Lood1 and Tomas Mustelin1, 1University of Washington, Seattle, WA, 2Massachusetts General Hospital, Boston, MA, 3Rockefeller University, New York, NY, 4Department of Pediatrics, Northwestern University Feinberg School of Medicine; The Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Pediatric Rheumatology; The CureJM Center of Excellence in Juvenile Myositis Research and Care, The Stanley Manne Children's Research Center of Chicago, Lake Forest, IL, 5Seattle Children's Hospital, Seattle, WA

    Background/Purpose: To quantitate autoantibodies against the RNA-binding p40 (ORF1p) protein encoded by the L1 retroelement, expression of p40 itself, and markers of neutrophil death in…
  • Abstract Number: 2031 • ACR Convergence 2020

    Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis

    Augusta Ortolan1, Victoria Navarro-Compán2, Alexandre Sepriano3, Robert Landewé4, Désirée van der Heijde5 and Sofia Ramiro6, 1Leiden University Medical Center, Padova, Italy, 2Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, 3Leiden University Medical Center, Portela Loures, Portugal, 4Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, 5Leiden University Medical Center, Leiden, Netherlands, 6Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: Several disease activity response and status criteria are used to assess treatment efficacy in RCTs in axial spondyloarthritis (axSpA). Response criteria include: the Assessment…
  • Abstract Number: 033 • 2020 Pediatric Rheumatology Symposium

    Parental Adverse Childhood Experience (ACE) Exposure Is Predictive of Active Lupus in Pediatric Patients

    Michael Nelson1, Nancy Correa 2, Ashley Butler 1, Marietta De Guzman 3, Bethanie Van Horne 1 and Christopher Greeley 1, 1Baylor College of Medicine, Houston, 2Texas Children's Hospital, Houston, 3Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas

    Background/Purpose: Adverse Childhood Experiences (ACEs) have been recognized for more than two decades as risk factors for poor health outcomes in adults. Nevertheless, the impact…
  • Abstract Number: 071 • 2020 Pediatric Rheumatology Symposium

    Patient Reported Outcomes and Resilience in Pediatric Systemic Lupus Erythematosus

    Lauren Ambler1, Rula Issa 2, Stephanie Pan 2 and Rebecca Trachtman 2, 1Mount Sinai Hospital, New York, 2Icahn School of Medicine at Mount Sinai, New York

    Background/Purpose: It has been established that pediatric Systemic Lupus Erythematous (pSLE) is associated with lower health-related quality of life (HRQOL); however, there are few studies…
  • Abstract Number: 078 • 2020 Pediatric Rheumatology Symposium

    Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma

    Suzanne Li1, Mara Becker 2, Sandy Hong 3, Polly Ferguson 4, Themba Nyrienda 5, Tracy Andrews 6, Katie Stewart 7, C. Egla Rabinovich 8, Robert Fuhlbrigge 9, Thomas Mason 10, Elena Pope 11, Maria Ibarra 12, Fatma Dedeoglu 13, Gloria Higgins 14, Ronald Laxer 15, Marilynn Punaro 16 and Kathryn Torok 17 for the CARRA investigators, 1Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, 2Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, 3University of Iowa Stead Family Children's Hospital, Iowa City, 4University of Iowa Carver College of Medicine, Iowa City, 5Hackensack Univesity Medical Center, Hackensack, 6Rutgers University, Newark, 7UT Southwestern, Dallas, 8Duke University Hospital, Durham, 9University of Colorado, Aurora, 10Rochester, 11Hospital For Sick Kids, Toronto, Canada, 12Children's Mercy Kansas City, Kansas City, 13Boston Children's Hospital, Boston, 14Nationwide Childrens Hospital/ The Ohio State University, Columbus, 15The Hospital for Sick Children and University of Toronto, Toronto, Canada, 16Dallas, Texas, 17Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh

    Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease. Treatment is directed towards controlling disease activity to minimize risk for functional impairment…
  • Abstract Number: 128 • 2020 Pediatric Rheumatology Symposium

    Predictors of Moderate/High Disease Activity in Childhood-Onset Systemic Lupus Erythematosus

    Emily Smitherman1, Rouba Chahine 1, Timothy Beukelman 1, Andrea Knight 2, AKM Fazlur Rahman 1, Mary Beth Son 3, Jeffrey R Curtis 4 and Aimee Hersh 5 for the CARRA investigators, 1University of Alabama at Birmingham, Birmingham, 2SickKids Research Institute, Toronto, Canada, 3Boston Children's Hospital, Boston, Massachusetts, 4University of Alabama at Birmingham, Hoover, 5University of Utah Primary Children's Hospital, Salt Lake City

    Background/Purpose: Substantial risk of early morbidity and mortality exists for patients with childhood-onset systemic lupus erythematosus (cSLE), but there are limited studies identifying predictors of…
  • Abstract Number: 139 • 2020 Pediatric Rheumatology Symposium

    Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study

    Mia Glerup1, Ellen D Arnstad 2, Veronika Rypdal 3, Suvi Peltoniemi 4, Kristiina Aalto 5, Marite Rygg 6, Susan Nielsen 7, Anders Fasth 8, Lillemor Berntson 9, Ellen Nordal 3 and Troels Herlin 10, 1Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, 2Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, and Department of Pediatrics, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Tromheim, Norway, 3Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, 4Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., Helsinki, Finland, 5Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, 6Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, 7Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhagen, Denmark, 8Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, 9Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, 10Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark

    Background/Purpose: Previously, we showed that ILAR JIA categories defined at disease onset change considerably during the first 8 years of disease course. Whether achieved remission…
  • Abstract Number: L17 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial

    Eric Morand1, Richard Furie 2, Yoshiya Tanaka 3, Ian Bruce 4, Anca Askanase 5, Christophe Richez 6, Sang-Cheol Bae 7, Philip Brohawn 8, Lilia Pineda 9, Anna Berglind 10 and Raj Tummala 9, 1Monash University, Melbourne, Victoria, Australia, 2Zucker School of Medicine at Hofstra/Northwell, New York, 3University of Occupational and Environmental Health, Kitakyushu, Japan, 4University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, 5Columbia University, New York, 6CHU de Bordeaux-GH Pellegrin, Bordeaux, France, 7Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 8Former employee of AstraZeneca, Gaithersburg, Maryland, 9AstraZeneca, Gaithersburg, Maryland, 10AstraZeneca, Gothenburg, Sweden

    Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…
  • Abstract Number: 473 • 2019 ACR/ARP Annual Meeting

    RA Presents in Disease Patterns Impacting Treatment Response

    Kathryne Marks1, Dana Symons 2, Cynthia Crowson 3, Pamela Sinicrope 4 and Kelly O'Neill 5, 1Rosalind Franklin University of Medicine and Science, Gurnee, IL, 2Rheumatoid Patient Foundation, Inc., Rockford, MI, 3Mayo Clinic Rochester, Rochester, 4Mayo Clinic, Rochester, MN, 5Rheumatoid Patient Foundation, Inc., Winter Springs, FL

    Background/Purpose: Despite significant research on rheumatoid arthritis (RA), disease courses have not been clearly described. Like systemic lupus erythematosus and multiple sclerosis, RA displays a…
  • Abstract Number: 1537 • 2019 ACR/ARP Annual Meeting

    Concomitant Treatment with Methotrexate Does Not Increase the Efficacy of Ustekinumab or TNF Inhibitors in Psoriatic Arthritis: Results from a Real-world, Multicenter Study

    Stefan Siebert1, Elisa Gremese 2, Paul Bergmans 3, Kurt De Vlam 4, Beatriz Joven-Ibáñez 5, Gkikas Katsifis 6, Tatiana Korotaeva 7, Wim Noël 8, Carlo Selmi 9, Petros Sfikakis 10, Pavel Smirnov 11, Elke Theander 12, Michael Nurmohamed 13, Laure Gossec 14 and Josef Smolen 15, 1Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy, 3Biostatistics and Medical Affairs, Janssen, Tilburg, Netherlands, 4University Hospitals Leuven, Leuven, Belgium, 5Hospital Universitario 12 de Octubre, Madrid, Spain, 6Naval Hospital of Athens, Rheumatology Clinic, Athens, Greece, 7Nasonova Research Institute of Rheumatology, Moscow, Russia, 8Biostatistics and Medical Affairs, Janssen, Brussels, Belgium, 9Humanitas Research Hospital, University of Milan, Milan, Italy, 10Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, 11Biostatistics and Medical Affairs, Janssen, Moscow, Russia, 12Biostatistics and Medical Affairs, Janssen, Solna, Sweden, 13Reade and VU Rheumatology Research Department, Amsterdam, Netherlands, 14Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, 15Medical University of Vienna, Vienna, Austria

    Background/Purpose: The additional benefit of methotrexate as a concomitant treatment in PsA has not been fully elucidated. Observational data exist for concomitant methotrexate (MTX) use…
  • Abstract Number: 502 • 2019 ACR/ARP Annual Meeting

    Disease Activity Measures at Baseline and 3 Months as Predictors of Rapid Radiographic Progression in Methotrexate Naïve Patients with Early Rheumatoid Arthritis

    Mohammad Movahedi 1, Deborah Weber 1, Pooneh Akhavan 2 and Edward Keystone3, 1Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, 2Division of Rheumatology, Mount Sinai Hospital, Toronto, Canada, 3Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada

    Background/Purpose: Progressive rheumatoid arthritis (RA) is responsible for disabilities in this patient population, characterized by radiographic joint damage. Achieving low disease activity (LDA) in RA…
  • Abstract Number: 1559 • 2019 ACR/ARP Annual Meeting

    Routine Clinical Pathology Measurements Are Predictive of the Risk of Organ Damage Accrual in SLE

    Eric Morand1, Kevin Zhang 1, Sarah Boyd 1, Francois Petitjean 1, Alberta Hoi 2, Rachel Koelmeyer 1 and Hieu Nim 1, 1Monash University, Melbourne, Victoria, Australia, 2School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia

    Background/Purpose: Prevention of permanent organ damage, a major predictor of morbidity and mortality, is a key goal in the treatment of SLE. Physician-measured disease activity…
  • Abstract Number: 564 • 2019 ACR/ARP Annual Meeting

    ASDAS Is More Important Than BASDAI in Advanced Ankylosing Spondylitis

    Jae-Bum Jun1, Bon San Koo 2, Seunghun Lee 3, Jinju Kim 4, Juyeon Kang 1 and Tae-Hwan Kim 1, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 2Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea, 3Dertment of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 4Novartis Korea Ltd., Seoul

    Background/Purpose: In patients with ankylosing spondylitis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to measure disease activity to initiate or maintain TNF…
  • Abstract Number: 1615 • 2019 ACR/ARP Annual Meeting

    The Effects of Anti-glutamate Receptor Subunit Antiantibodies on Systemic Lupus Erythematosus Without Neuropsychiatric Involvement

    Yoshiyuki Arinuma 1, Yasuhiro Hasegawa 1, Takumi Muramatsu1, Yu Matsueda 1 and Kunihiro Yamaoka 1, 1Department of Rheumatology and Infectious Diseaes, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

    Background/Purpose: Autoantibodies against N-methyl-D-aspartate receptor subunit GluN2 (anti-GluN2) in the cerebrospinal fluid are known to be related with the development of diffuse psychiatric/neuropsychological manifestations in…
  • « Previous Page
  • 1
  • …
  • 56
  • 57
  • 58
  • 59
  • 60
  • …
  • 112
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology